Key Highlights

  • TG Therapeutics (NASDAQ:TGTX) lifted its 2026 Revenue outlook to around USD 1 billion, helped by a 52% jump in US BRIUMVI sales, the lone drug it sells.
  • Ceva slid roughly 8% once a sizable multi-year connectivity deal, anticipated for the third quarter, was inked early in the fourth, keeping revenue growth to 2%.
  • Quantum Computing Inc topped revenue forecasts with USD 9.5 million, fueled by acquired operations, while interest income, at USD 13.0 million, was bigger than the revenue figure.
  • Each quarter pivoted on one element, a single product, a lone contract or one source of revenue, a pattern that spreads exposure in several distinct ways.

1. Quantum Computing Inc (NASDAQ:QUBT) and Acquisition-Led Revenue

Quantum Computing Inc (NASDAQ:QUBT) booked USD 9.5 million of revenue for the third quarter of 2026 on November 9, beating the roughly USD 7.6 million analysts had penciled in and rising from USD 384,000 a year earlier. The quarter alone surpassed the company's full first-half 2026 revenue of USD 9.2 million. The lever is acquisition: the gain came from photonics and semiconductor units purchased earlier this year, not Organic Sales of quantum systems. The wider financials make the same point. The company lost USD 15.1 million, or USD 0.07 a share, while interest and other income of USD 13.0 million exceeded revenue; that income was generated by cash, equivalents and investments of roughly USD 1.3 billion. Backlog under contract came to near USD 39.1 million. Of the three, QUBT carries the most risk: the beat reveals little about Demand for its own technology, and the stock tends to move with sentiment toward quantum computing overall.

2. Licensing Timing Slip at Ceva (NASDAQ:CEVA)

Ceva (NASDAQ:CEVA) lost roughly 8% on November 9, as third-quarter revenue of USD 29.1 million grew only 2% year over year and fell short of expectations. Management blamed timing: a major multi-year connectivity license that was supposed to close in the third quarter was executed early in the fourth, shifting that revenue into the next period. Beneath the headline, operations improved. Royalties grew 18% sequentially to USD 12.7 million, helped by a large US customer scaling up its own smartphone modems, AI licensing reached a record, and non-GAAP Earnings moved up to USD 0.13 a share, compared with USD 0.11. On a GAAP basis the company lost USD 2.3 million. Risk is moderate: the contract is already signed, so the question is how much appears in fourth-quarter revenue, though lumpy licensing makes quarterly results hard to predict.

3. One-Drug Concentration at TG Therapeutics (NASDAQ:TGTX)

TG Therapeutics (NASDAQ:TGTX) announced, on November 9, third-quarter global sales of USD 259.9 million, a gain of roughly 60.7% that topped the USD 245.5 million consensus. US net product sales of BRIUMVI, its multiple sclerosis medicine, grew about 52% to USD 232.6 million. The company increased its 2026 global revenue outlook to around USD 1 billion and nudged US BRIUMVI guidance up to USD 915 million to USD 920 million, against a prior USD 890 million to USD 905 million. Diluted earnings came to USD 0.35 a share, a cent under consensus, as research spending increased, while Net Income came in at USD 55.5 million. Depending on a single marketed drug is a concentration risk, yet this is a profitable, fast-growing one. A Phase 3 readout for the subcutaneous version, due near year-end, and USD 556.7 million in cash give TG room to broaden the franchise, which is why it looks least risky here.

Where Things Stand

Of the top 3 single-driver quarters of November 9, Quantum Computing Inc bears the most risk, because its revenue beat came from acquired operations while interest income still outruns sales. Ceva's risk is one of timing: the late license is now signed, and royalties climbed 18% sequentially. TG Therapeutics leans on a single product, BRIUMVI, yet that product is growing about 52% and backs a USD 1 billion outlook. Watch Ceva's fourth-quarter revenue and the subcutaneous Phase 3 results from TG next.